Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Asset disposition Quarterly results Inv. presentation
|
Outlook Therapeutics, Inc. (ONS)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/25/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
08/14/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/14/2023 |
8-K
| Quarterly results
Docs:
|
"Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones · Prescription Drug User Fee Act goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration ISELIN, N.J., August 14, 2023 — Outlook Therapeutics, Inc. , a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of wet AMD, today announced recent corporate highlights and financial results for its fiscal third quarter ended June 30, 2023. Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, commented, “We continue to be focused on our pre-launch activi..." |
|
05/16/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
05/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits... |
05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/15/2023 |
8-K
| Quarterly results |
04/03/2023 |
8-K/A
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
02/14/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
02/14/2023 |
8-K
| Quarterly results |
01/27/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
01/24/2023 |
10-K/A
| Annual Report for the period ended September 30, 2022 [amend] |
01/06/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
01/06/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
12/29/2022 |
10-K
| Annual Report for the period ended September 30, 2022 |
12/29/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
12/29/2022 |
8-K
| Quarterly results |
12/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
12/23/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
12/22/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs:
|
"Exhibit E",
"EXHIBIT A",
"Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD · Decision for potential approval expected from European Commission in early 2024 · Submission follows the U.S. FDA acceptance of the ONS-5010 BLA for wet AMD, with a PDUFA date of August 29, 2023 ISELIN, N.J., December 22, 2022 — Outlook Therapeutics, Inc. , a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the validation of its Marketing Authorization Application by the European Medicines Agency for ONS-5010 / LYTENAVA™ , an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related ..." |
|
11/23/2022 |
8-K
| Quarterly results |
08/15/2022 |
8-K
| Quarterly results |
08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
08/10/2022 |
8-K
| Quarterly results |
07/07/2022 |
SC 13D/A
| Tenshi Healthcare Pte. Ltd. reports a 10.2% stake in Outlook Therapeutics, Inc. |
07/07/2022 |
SC 13D
| GMS Ventures & Investments reports a 25.1% stake in Outlook Therapeutics, Inc. |
06/17/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
06/17/2022 |
8-K
| Quarterly results |
06/07/2022 |
8-K
| Quarterly results |
05/31/2022 |
8-K
| Quarterly results |
05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
05/13/2022 |
8-K
| Quarterly results |
04/22/2022 |
SC 13D/A
| Tenshi Healthcare Pte. Ltd. reports a 25.6% stake in Outlook Therapeutics, Inc. |
|
|
|